Novartis revamps commercial strategy as Entresto patent cliff looms
With its decadelong US patent for Entresto set to expire in a few months, Novartis has started to overhaul its commercial approach. The drugmaker is laying off hundreds of employees and will instead focus on ...
With its decadelong US patent for Entresto set to expire in a few months, Novartis has started to overhaul its commercial approach. The drugmaker is laying off hundreds of employees and will instead focus on ...
